
    
      Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo
      administered in addition to standard therapy. Following the baseline visit, subjects will be
      expected to return for clinic visits at 1 month, 3 months, 6 months and every 6 months until
      the end of the study.
    
  